肺动脉高压临床试验参与者的新型肝损伤表型与结局
该研究对1998至2014年间15项随机临床试验中肺动脉高压(PAH)和慢性血栓栓塞性肺动脉高压(CTEPH)患者进行无监督机器学习聚类,识别出无肝损伤、肝细胞损伤、胆汁淤积性损伤和混合损伤四种肝损伤表型,发现胆汁淤积性损伤患者临床恶化时间最短且死亡风险最高,随机分配至实验治疗组可改善肝脏状态。
要点
- PAH和CTEPH患者可聚类为无肝损伤、肝细胞损伤、胆汁淤积性损伤和混合损伤四种表型。
- 胆汁淤积性损伤表型患者临床恶化时间最短、死亡风险最高。
- 随机分配至实验治疗组可使患者肝脏状态向更健康方向转变。
核心结论
- 肝损伤与PAH和CTEPH患者的不良结局相关。
- 与安慰剂相比,随机分配至活性治疗对肝脏健康有有益影响。
研究设计与样本
- 研究纳入1998至2014年间15项随机临床试验中的PAH和CTEPH患者。
- 使用无监督机器学习在13项试验中识别肝损伤聚类,并在另外2项试验中验证。
- 训练数据集包括4,219例患者,验证数据集包括1,756例患者。
主要发现
- 使用k-means聚类识别出无肝损伤、肝细胞损伤、胆汁淤积性损伤和混合损伤模式。
- 胆汁淤积性损伤肝聚类患者临床恶化时间最短且死亡风险最高。
- 胆汁淤积性损伤组在6分钟步行距离上安慰剂校正的治疗效应最大。
- 随机分配至实验组使患者肝脏状态向更健康转变。
临床怎么用
- 在PAH和CTEPH患者中应关注肝损伤表型,尤其是胆汁淤积性损伤,其与不良结局相关。
局限性
- 肝病(常为亚临床)在决定结局中的作用需要前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) cause right ventricular dysfunction, which can impact other solid organs. However, the profiles and consequences of hepatic injury resulting from PAH and CTEPH have not been well studied. Objectives: We aimed to identify underlying patterns of liver injury in a cohort of patients with PAH and CTEPH enrolled in 15 randomized clinical trials conducted between 1998 and 2014. Methods: We used unsupervised machine learning to identify liver injury clusters in 13 trials and validated the findings in two additional trials. We then determined whether these liver injury clusters were associated with clinical outcomes or treatment effect heterogeneity. Measurements and Main Results: Our training dataset included 4,219 patients and our validation dataset included 1,756 patients with serum total bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, and albumin data. Using k-means clustering, we identified phenotypes with no liver injury, hepatocellular injury, cholestatic injury, and combined injury patterns. Patients in the cholestatic injury liver cluster had the shortest time to clinical worsening and the highest risk of mortality. The cholestatic injury group also experienced the greatest placebo-corrected treatment effect on 6-minute-walk distance. Randomization to the experimental arm transitioned patients to a healthier liver status. Conclusions: Liver injury was associated with adverse outcomes in patients with PAH and CTEPH. Randomization to active treatment had beneficial effects on liver health compared with placebo. The role of liver disease (often subclinical) in determining outcomes warrants prospective studies.
引用
- Scott JV, Moutchia J, McClelland RL, et al. Novel Liver Injury Phenotypes and Outcomes in Clinical Trial Participants with Pulmonary Hypertension. Am J Respir Crit Care Med. 2024. PMID: 38820270. doi:10.1164/rccm.202311-2196OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。